TY - JOUR T1 - SARS-CoV-2 RNA in urban wastewater samples to monitor the COVID-19 epidemic in Lombardy, Italy (March – June 2020) JF - medRxiv DO - 10.1101/2021.05.05.21256677 SP - 2021.05.05.21256677 AU - Sara Castiglioni AU - Silvia Schiarea AU - Laura Pellegrinelli AU - Valeria Primache AU - Cristina Galli AU - Laura Bubba AU - Federica Mancinelli AU - Marilisa Marinelli AU - Danilo Cereda AU - Emanuela Ammoni AU - Elena Pariani AU - Ettore Zuccato AU - Sandro Binda Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/09/2021.05.05.21256677.abstract N2 - Wastewater-based viral surveillance is a promising approach to monitor the circulation of SARS-CoV-2 in the general population. The aim of this study was to develop an analytical method to detect SARS-CoV-2 RNA in urban wastewater, to be implemented in the framework of a surveillance network in the Lombardy region (Northern Italy). This area was the first hotspot of COVID-19 in Europe. Composite 24h samples were collected weekly in eight cities from end-March to mid-June 2020 (first peak of the epidemic). The method developed and optimized, involved virus concentration, using PEG centrifugation, and one-step real-time RT-PCR for analysis. SARS-CoV-2 RNA was identified in 65 (61%) out of 107 samples, and the viral concentrations (up to 2.1 E +05 copies/L) were highest in March-April. By mid-June, wastewater samples tested negative in all the cities. Viral loads were used for inter-city comparison and Brembate, Ranica and Lodi had the highest. The pattern of decrease of SARS-CoV-2 in wastewater was closely comparable to the decline of active COVID-19 cases in the population, reflecting the effect of lock-down. Wastewater surveillance of SARS-CoV-2 can integrate ongoing virological surveillance of COVID-19, providing information from both symptomatic and asymptomatic individuals, and monitoring the effect of health interventions.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialnoneFunding StatementThe study did not had specific funds, it was run with internal resources from our Institutions.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study did not required ethical approval by a committeeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesthe manuscript contains in the text and in the Supplementray material all the data produced. ER -